Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | cytochrome P450 51B1 Cyp51B1 | 0.03 | 0.8036 | 0.5 |
Trypanosoma cruzi | Lanosterol 14-alpha demethylase | 0.03 | 0.8036 | 0.5 |
Mycobacterium tuberculosis | Cytochrome P450 51 Cyp51 (CYPL1) (P450-L1A1) (sterol 14-alpha demethylase) (lanosterol 14-alpha demethylase) (P450-14DM) | 0.03 | 0.8036 | 1 |
Schistosoma mansoni | integrin beta subunit | 0.0207 | 0.496 | 0.5 |
Echinococcus granulosus | integrin beta 2 | 0.0263 | 0.6823 | 0.5 |
Leishmania major | lanosterol 14-alpha-demethylase, putative | 0.03 | 0.8036 | 0.5 |
Trypanosoma brucei | Lanosterol 14-alpha demethylase | 0.03 | 0.8036 | 0.5 |
Loa Loa (eye worm) | integrin beta-2 | 0.0359 | 1 | 1 |
Echinococcus multilocularis | integrin beta 2 | 0.0263 | 0.6823 | 0.5 |
Trypanosoma cruzi | Lanosterol 14-alpha demethylase | 0.03 | 0.8036 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.